Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Gen-Probe's Trichomonas Assay

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has approved Gen-Probe's Aptima Trichomonas vaginalis assay for its automated Tigris platform, the company announced today.

The assay is the first amplified nucleic acid test cleared specifically for Trichomonas vaginalis, the most common curable sexually transmitted infection in the US, where 7.4 million men and women are infected annually, Gen-Probe said, citing statistics from the US Centers for Disease Control and Prevention.

It added that current screening methods for trichomonas — culture methods and "wet mount," where samples are analyzed shortly after collection — are limited by sensitivity and slow turnaround times.

Gen-Probe's assay can be used to test endocervical or vaginal swabs collected by clinicians, urine, and specimens collected in PreservCyt solution from asymptomatic as well as symptomatic women.

"Our assay will provide a convenient tool for physicians an laboratories because it employs the same technology as our market-leading tests for chlamydia and gonorrhea, can be used with the same female samples, and runs on our unique, fully automated Tigris system," Carl Hull, president and CEO of Gen-Probe, said in a statement.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.